Literature DB >> 26603346

Identification of a novel de novo mutation of CREBBP in a patient with Rubinstein-Taybi syndrome by targeted next-generation sequencing: a case report.

Kunka Kamenarova1, Emil Simeonov2, Reni Tzveova3, Daniela Dacheva3, Marin Penkov4, Ivo Kremensky5, Penka Perenovska2, Vanio Mitev3, Radka Kaneva3.   

Abstract

Rubinstein-Taybi syndrome (RSTS) is a rare autosomal dominant congenital disorder (prevalence, 1:125000-720000) characterized by broad thumbs and halluces, facial dysmorphism, psychomotor development delay, skeletal defects, abnormalities in the posterior fossa, and short stature. The purpose of this study was to use targeted exome sequencing to identify the genetic cause of RSTS in a 6.5-year-old girl presenting typical features of this condition. Targeted exome sequencing of the patient DNA revealed de novo transition c.1066C>T corresponding to a novel nonsense mutation p.Q356X in the CREB-binding protein gene, CREBBP, whose haploinsufficiency is responsible for 50% to 60% of the RSTS cases. Based on comparing the clinical manifestations of our patient with those of patients carrying similar mutations, we supposed that haploinsufficiency is the possible functional consequence of p.Q356X mutation by creation of a loss-of-function CREBBP allele due to a premature stop codon and RSTS phenotype. Our findings expand the spectrum of mutations associated with this condition.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CREB binding protein; Genotype-phenotype correlation; Novel mutation; Rubinstein-Taybi syndrome; Targeted exome sequencing

Mesh:

Substances:

Year:  2015        PMID: 26603346     DOI: 10.1016/j.humpath.2015.09.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  1 in total

1.  First case report of inherited Rubinstein-Taybi syndrome associated with a novel EP300 variant.

Authors:  María López; Verónica Seidel; Paula Santibáñez; Cristina Cervera-Acedo; Pedro Castro-de Castro; Elena Domínguez-Garrido
Journal:  BMC Med Genet       Date:  2016-12-13       Impact factor: 2.103

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.